Chicago Partners Investment Group LLC Makes New Investment in Insulet Corporation $PODD

Chicago Partners Investment Group LLC acquired a new position in Insulet Corporation (NASDAQ:PODD) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 769 shares of the medical instruments supplier’s stock, valued at approximately $220,000.

Other institutional investors have also made changes to their positions in the company. Zions Bancorporation National Association UT bought a new position in shares of Insulet in the first quarter worth about $26,000. Larson Financial Group LLC increased its stake in shares of Insulet by 426.3% in the first quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier’s stock worth $26,000 after purchasing an additional 81 shares during the period. SouthState Corp increased its stake in shares of Insulet by 253.3% in the first quarter. SouthState Corp now owns 106 shares of the medical instruments supplier’s stock worth $28,000 after purchasing an additional 76 shares during the period. Kozak & Associates Inc. bought a new position in shares of Insulet in the second quarter worth about $32,000. Finally, Trust Co. of Toledo NA OH bought a new position in shares of Insulet in the second quarter worth about $35,000.

Insider Activity at Insulet

In other news, SVP Laetitia Cousin sold 797 shares of the company’s stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $348.81, for a total value of $278,001.57. Following the sale, the senior vice president directly owned 3,890 shares in the company, valued at approximately $1,356,870.90. This represents a 17.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Prem Singh sold 687 shares of the company’s stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the completion of the sale, the senior vice president owned 3,456 shares in the company, valued at approximately $1,200,925.44. This represents a 16.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.39% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. Jefferies Financial Group reiterated a “buy” rating on shares of Insulet in a research note on Thursday, August 7th. Rothschild & Co Redburn lifted their price objective on Insulet from $350.00 to $370.00 and gave the stock a “buy” rating in a research note on Friday, October 3rd. Canaccord Genuity Group lifted their price objective on Insulet from $353.00 to $399.00 and gave the stock a “buy” rating in a research note on Monday, September 29th. Oppenheimer boosted their price target on Insulet from $324.00 to $365.00 and gave the company an “outperform” rating in a research note on Monday, September 8th. Finally, The Goldman Sachs Group lowered their price target on Insulet from $399.00 to $375.00 and set a “buy” rating on the stock in a research note on Wednesday, October 1st. One investment analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $352.11.

Insulet Trading Down 0.8%

PODD stock opened at $320.91 on Friday. Insulet Corporation has a 1-year low of $226.50 and a 1-year high of $353.50. The firm has a market cap of $22.59 billion, a P/E ratio of 97.54, a P/E/G ratio of 2.68 and a beta of 1.40. The business’s 50 day moving average is $327.60 and its 200-day moving average is $304.83. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, beating the consensus estimate of $0.92 by $0.25. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The company had revenue of $649.10 million for the quarter, compared to analyst estimates of $612.31 million. During the same period in the prior year, the company posted $0.55 EPS. The company’s revenue was up 32.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Equities analysts anticipate that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.